Ariti
Ariti is a Greek pharmaceutical and medical device distributor founded in 1985 that supplies hospitals, clinics, and pharmacies in Greece and Cyprus across oncology, urology, CNS, rare diseases, and medical devices, while also operating 10 private dialysis units.
- Company typePrivate
- Founded1985
- HeadquartersAcharnae, Greece
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Ariti does
Ariti is a Greek pharmaceutical and medical technology distribution company founded in 1985, headquartered in Greece and operating across both Greece and Cyprus. The company distributes pharmaceuticals across oncology, urology, central nervous system, and rare diseases therapeutic areas, alongside medical devices spanning dialysis machines, catheters, orthopaedic implants, and surgical products. Its core business model rests on long-standing exclusive distribution agreements with international manufacturers, combined with vertical integration into clinical services through 10 private dialysis units across Greece.
The company operates through distinct divisions covering pharmaceuticals, medical devices, and rare diseases, the last of which was established as a dedicated business unit in 2019 to commercialize orphan drugs. Revenue mechanics are anchored in product-margin distribution, recurring sales to hospitals, clinics, and pharmacies, and per-treatment revenue from owned dialysis facilities. Exclusive partnerships with manufacturers such as Rhythm Pharmaceuticals, Oncopeptides, Insmed, and Ayrmid anchor the specialty pharma franchise.
Ariti's go-to-market relies on registered pharmaceutical and medical-device products within the Hellenic National Organization for Medicines (EOF) framework and EOPPY reimbursement system, with the Cyprus market providing geographic diversification. Membership in the Your Products Partners (YPP) international distribution network since 2026 signals continued principal-acquisition momentum. Customer end-markets are hospitals, dialysis patients, and licensed healthcare professionals across both jurisdictions.
Ariti firmographics
Firmographics- Name
- Ariti
- Legal name
- ΑΡΗΤΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΠΡΟΪΟΝΤΩΝ
- Website
- https://ariti.gr
- Company type
- Private
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Ariti is a Greek pharmaceutical and medical device distributor founded in 1985 that supplies hospitals, clinics, and pharmacies in Greece and Cyprus across oncology, urology, CNS, rare diseases, and medical devices, while also operating 10 private dialysis units.
- Ownership category
- akta.pro rank
Ariti industry classification
Industry- Product category
- Pharmaceutical and Medical Device Distribution
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
- akta.pro secondary industry
- Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)
Keywords
Where Ariti is headquartered
LocationHeadquarters
- HQ city
- Acharnae
- HQ country
- Greece
- HQ region
- Europe
Offices3 records
Markets served
Ariti business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D
Revenue model
- Pharmaceutical Product Distribution: Distribution and sale of proprietary and licensed pharmaceutical products across oncology, nephrology, urology, CNS, and rare diseases in Greece and Cyprus. Revenue is generated through product sales to hospitals, pharmacies, and healthcare providers. Products include Letrafem (letrozole), Rectoxal (oxaliplatin), Irican (irinotecan), Topocan (topotecan), Gemlag (gemcitabine), Capibine (capecitabine), Sunitinib, and specialty products in urology and CNS categories.
- Medical Technology / Medical Device Distribution: Exclusive commercial representation and distribution of internationally recognized medical device brands in Greece. Product categories include hemodialysis machines and consumables, urology catheters (LoFric line), orthopaedic implants (shoulder, knee, hip arthroplasty), surgical products (wound drains, suction tips, hemorrhoid ligators), laboratory refrigerators and freezers, and therapy chairs. Revenue derived from device sales and consumables to hospitals and dialysis clinics.
- Dialysis Center Services: Operation of a network of 10 Private Dialysis Units (Protypo Nephrology Centers) providing haemodialysis services to renal patients. Centers are located in Athens, Piraeus, Attica, Galatsi, Ilion, Thessaloniki, Pella, Komotini, Patra, and Maniatika Piraeus.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Ariti product offering
Product offeringCore offering
Ariti S.A. is a Greek pharmaceutical and medical technology distributor that serves as the exclusive commercial representative of international manufacturers in Greece and Cyprus. The company distributes proprietary and licensed pharmaceuticals (oncology, urology, CNS, nephrology, rare diseases) and medical devices (dialysis machines and consumables, urology catheters, orthopedic implants, surgical consumables). In parallel, Ariti operates 10 private hemodialysis units (Protypo Nephrology Centers) across Greece, making it a vertically integrated distributor-and-service-provider.
Product overview
Ariti S.A. is a Greek pharmaceutical and medical technology company founded in 1985, operating through two integrated divisions: MedTech Products (medical devices) and a Pharmaceutical Division. The MedTech division encompasses renal/dialysis products (modern dialysis machines, filters, catheters, fistula needles, CRRT systems, water treatment), urology catheters (LoFric product line, Navina irrigation), orthopedics (shoulder, knee, hip arthroplasty, traumatology), surgery equipment (wound drains, autologous reinfusion, hemorrhoid ligators), and laboratory equipment (refrigerators, freezers, therapy chairs). The pharmaceutical division covers oncology (Letrafem, Rectoxal, Irican, Topocan, Gemlag, Capibine, Sunitinib), urology (Abiraterone, Alfuzin, Lutrak, Solicin, Tamsulosin, Tadalafil), CNS (Quetiapine, Peziled, Escitalopram, Memantine, Prazarit, Rasagiline), nephrology (Reoxyl, Aricitol), small-volume injections, OTC, rare diseases (NTM lung disease with Arikayce), and hematology (Lenalidomide). Ariti also operates dialysis units across Greece and maintains pharmacovigilance and medical device vigilance programs.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 10 Private Dialysis Units providing haemodialysis services across Greece
- +1 more outcomes
Companies that use Ariti
Customer profileNamed customers3 records
Segments8 records
Ideal customer profiles3 records
Ariti technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ariti partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered moderate, minor and core.
- Your Pharma Partner in Europe (YPP) NetworkmoderateAriti joined the Your Pharma Partner in Europe (YPP) network, an alliance of independent pharmaceutical companies established to support pharmaceutical market access across Europe. This membership strengthens Ariti's strategic presence in the European pharmaceutical sector and expands opportunities for developing new partnerships.
- Ayrmid Ltd. / Gamida Cell Inc.minorAriti signed an exclusive distribution agreement with Ayrmid (parent company of Gamida Cell Inc.) for the distribution of Omisirge (Omidubicel-onlv) in Greece and Cyprus. Omisirge is a nicotinamide-modified allogeneic hematopoietic bone marrow-derived lineage stem cell therapy.
- Rhythm Pharmaceuticals, Inc.coreAriti announced a strategic partnership with Rhythm Pharmaceuticals (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Through this collaboration, Ariti spearheads multiple initiatives to raise awareness of rare melanocortin-4 receptor (MC4R) pathway diseases in Greece.
- Oncopeptides ABminorOncopeptides AB (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, partnered with Ariti for first named patient sales of Pepaxti (melfalan flufenamide) in Greece. Ariti serves as the local distribution partner enabling access to this orphan oncology drug.
- Insmed Ireland LimitedcoreAriti and Insmed Ireland Limited signed an agreement for Greece, aiming to increase awareness of non-tuberculosis mycobacteria (NTM) pulmonary disease. This collaboration includes distribution of Arikayce (amikacin liposome inhalation suspension) for NTM lung disease, reinforcing Ariti's rare disease and orphan drug portfolio.
- International Medical Technology and Pharmaceutical ManufacturerscoreAriti serves as exclusive commercial representative and distributor for internationally recognized medical technology and pharmaceutical manufacturers. Key brand relationships include LoFric catheters (Wellspect Healthcare/Astra Tech), TauroLock catheter locks (TauroPharma), and various pharmaceutical products from international developers. These partnerships span 35+ years and cover Ariti's entire product portfolio.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Ariti competitors and assessment
Company assessmentDirect peers
- Help Pharmaceuticals: Greek pharmaceutical company focused on oncology, supportive care, and specialty therapeutics. Comparable to Ariti's pharma division in product portfolio overlap and Greek market presence.
- Galenica: Greek pharmaceutical company operating across branded generics, consumer health, and medical devices. Comparable to Ariti in being a multi-category Greek healthcare distributor with national reach.
- Genesis Pharma: Greek pharmaceutical company specializing in oncology, hematology, and rare diseases with exclusive partnerships with international biotechs. Highly comparable to Ariti's rare disease unit and specialty pharma distribution model.
- Win Medica: Greek specialty pharmaceutical company with therapeutic focus areas including oncology, CNS, and rare diseases. Closely comparable to Ariti's pharma division portfolio and distribution approach.
- DEMO SA: Greek pharmaceutical manufacturer and distributor with broad hospital and retail coverage plus export activity. Comparable to Ariti as a Greek-headquartered pharma company with both manufacturing and distribution capabilities.
- Elpen Pharmaceutical: Greek pharmaceutical manufacturer and distributor with a broad therapeutic portfolio across multiple specialties. Directly comparable to Ariti as another Greek pharma company with national distribution scale and long operating history.
- Pharmathen: Greek pharmaceutical company with generics, specialty pharma, and rare disease focus plus international operations. Comparable to Ariti's therapeutic breadth and Greek-based market access capabilities.
- Mesogeios Dialysis Centers: Greek private dialysis center operator with multiple units. Comparable to Ariti's vertically integrated dialysis center operations, representing direct competition for renal patients and clinical referrals.
Broad incumbents
- Recordati: Italian-headquartered multinational pharmaceutical company with established operations in Greece. Comparable to Ariti in rare disease focus (Recordati Rare Diseases) and Greek market presence, though operating at much larger scale.
- B. Braun: Global medical device and pharmaceutical company with a major dialysis division and direct Greek operations. Comparable to Ariti's medical device distribution and dialysis-adjacent product portfolio, though as a multinational incumbent.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Ariti social profiles
Digital presenceAriti compliance and trust
Trust signalCompliance1 record
Ariti financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ariti leadership team
Management profileNumber of profiles
Ariti funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ariti M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ariti
What does Ariti do?
Ariti S.A. is a Greek pharmaceutical and medical technology distributor that serves as the exclusive commercial representative of international manufacturers in Greece and Cyprus. The company distributes proprietary and licensed pharmaceuticals (oncology, urology, CNS, nephrology, rare diseases) and medical devices (dialysis machines and consumables, urology catheters, orthopedic implants, surgical consumables). In parallel, Ariti operates 10 private hemodialysis units (Protypo Nephrology Centers) across Greece, making it a vertically integrated distributor-and-service-provider.
Is Ariti a public or private company?
Ariti is a private company. It is classified as unknown and is currently operating.
When was Ariti founded?
Ariti was founded in 1985. It employs 101 to 250 people.
Where is Ariti based?
Ariti is headquartered in Acharnae, Greece, in the Europe region.
How does Ariti make money?
Three revenue lines are on record. Pharmaceutical Product Distribution is the primary driver. The others are medical Technology / Medical Device Distribution and dialysis Center Services.
Who are Ariti's main competitors?
Direct peers on record are Help Pharmaceuticals, Galenica, Genesis Pharma, Win Medica, DEMO SA, Elpen Pharmaceutical, Pharmathen and Mesogeios Dialysis Centers. Broad incumbents are Recordati and B. Braun.
Does Ariti have an API?
No public API is recorded for Ariti.
What industry is Ariti in?
Ariti's product category is Pharmaceutical and Medical Device Distribution. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAIAI, Rare Renal & Nephrology Disorder Therapies. Its NAICS code is 42421 and its SIC code is 5122.